



**28 April 2017**

**Motif Bio plc**

("Motif Bio" or the "Company")

**Change of Nominated Adviser and Joint Broker**

Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, is pleased to announce the appointment of Peel Hunt LLP as nominated adviser and joint corporate broker with immediate effect.

**For further information please contact:**

**Motif Bio plc**

Graham Lumsden (Chief Executive Officer)

[info@motifbio.com](mailto:info@motifbio.com)

**Peel Hunt LLP (NOMAD & BROKER)**

Dr Christopher Golden  
Oliver Jackson

+ 44 (0)20 7418 8900

**Northland Capital Partners Limited (BROKER)**

Patrick Claridge/ David Hignell  
John Howes/ Rob Rees (Broking)

+44 (0)203 861 6625

**Walbrook PR Ltd. (FINANCIAL PR & IR)**

Paul McManus  
Mike Wort

+44 (0) 20 7933 8780 or [motifbio@walbrookpr.com](mailto:motifbio@walbrookpr.com)

Mob: +44 (0)7980 541 893

Mob: +44 (0)7900 608 002

**MC Services AG (EUROPEAN IR)**

Raimund Gabriel

+49 (0)89 210 2280

**Notes to Editors:**

Motif Bio is a clinical-stage biopharmaceutical company, engaged in the research and development of novel antibiotics designed to be effective against serious and life-threatening infections in hospitalised patients caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), infections often caused by MRSA (methicillin resistant *Staphylococcus aureus*). Having completed the REVIVE-1 trial, patients are currently being enrolled and dosed in a second global Phase 3 clinical trial (REVIVE-2) with an intravenous formulation of iclaprim, for the treatment of ABSSSI. Data readout for REVIVE-2 is expected in the second half of 2017.